Answers, evidence, clarity

Novilora™ is the registered U.S. product name for OnLife®, a nutritional supplement developed and produced in Italy. The OnLife® formulation combines specific fatty acids with palmitoylethanolamide (PEA) and was evaluated in the prospective, multicenter, single-arm observational STEFANO study in people with established chemotherapy-induced peripheral neuropathy (CIPN).

Yes. Novilora™ brings the established OnLife® product to customers in the United States under its registered U.S. name. Same formulation, same manufacturer, same published research.

No. Novilora™ is a nutritional supplement and does not require a prescription. It is not intended to diagnose, treat, cure, or prevent any disease.

CIPN stands for chemotherapy-induced peripheral neuropathy. It may involve symptoms such as numbness, tingling, burning, discomfort, or sensitivity, often affecting the hands and feet. Anyone experiencing these symptoms should discuss them with a qualified healthcare professional.

Until now, U.S. customers generally had to order the product from Europe. After international shipping and currency conversion, the total cost could exceed $100. Novilora™ is making the product available domestically for the first time.

Novilora™ is produced in Italy by an established pharmaceutical and supplement manufacturer.

Novilora™ will be on sale in the U.S. later this year, with initial inventory shipping in December 2026. You can join the interest list to be notified when it arrives.

Customers who are receiving cancer treatment, taking medications, pregnant or nursing, managing a medical condition, or considering a new supplement should consult their physician or another qualified healthcare professional before use.

Novilora's fatty acids and PEA were selected for their biological roles in neuronal cell membranes, myelin and peripheral nerve biology, cellular energy processes, neuroinflammatory signaling, and nerve communication. This scientific rationale does not by itself establish clinical efficacy.

Loading phase: take 2 tablets twice a day (2 in the morning and 2 in the evening, with food) for 8–10 days. Maintenance phase: continue with 1 tablet twice a day (morning and evening, with food) for at least three months. Optional maintenance: 1 tablet per day for an additional three months. Consult your healthcare provider about your individual use.

The STEFANO observational study evaluated OnLife® over three months. That study period does not guarantee an individual outcome. Follow the suggested use and discuss duration with your healthcare provider.

Novilora is built around palmitoylethanolamide (PEA) plus a defined fatty-acid profile that includes EPA and DHA, alpha-linolenic acid, linoleic acid, oleic acid, palmitic acid, and stearic acid. Refer to the package for the complete label and quantities.

Novilora is designed for people experiencing symptoms such as pain, tingling, burning, or numbness — and for those seeking a proactive, science-informed approach to supporting nerve health. Talk to your healthcare provider about whether Novilora is right for you.

Compatibility depends on your medications, supplements, treatment plan, and health history. Consult your healthcare provider before use; this website does not establish compatibility for an individual person.

Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide produced by the body, particularly in response to stress or injury. It has been studied for its role in supporting healthy inflammatory balance and nerve cell function.

Fatty acids are essential building blocks of cell membranes, including the myelin sheath that insulates nerves. Specific fatty acids support the structural raw materials nerves need to function well.